Rare diseases
Investigational molecules
Locations
Back to Italy2 684 clinical trials in Novara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis
ItalyStudy on Evolocumab for Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
ItalyStudy on EYE103 and Ranibizumab for Patients with Diabetic Macular Edema
ItalyStudy on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer
ItalyStudy of RO7790121 Treatment for Adults with Moderate to Severe Ulcerative Colitis: Testing Effectiveness and Safety in Initial and Long-term Therapy
ItalyStudy of RO7790121 Compared to Placebo for Treatment of Adults with Moderate to Severe Ulcerative Colitis
ItalyStudy on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 1
ItalyStudy of Tiragolumab and Atezolizumab for Patients with Advanced Non-Small Cell Lung Cancer
ItalyThe busiest research cities in the country
What the registry says about research in the country
Clinical trials focusing on hematologic malignancies and solid tumors, investigating innovative treatments for various cancer types including leukemia, breast cancer, and lung cancer.
Studies evaluating combination therapies and targeted treatments to improve patient outcomes.
Research focusing on heart failure prevention and treatment strategies, particularly exploring new drug combinations and their impact on cardiovascular outcomes.
Innovative approaches combining multiple therapeutic agents to address cardiovascular risks.
Investigations into treatments for various autoimmune disorders, including Sjögren's Syndrome and rheumatoid arthritis, with emphasis on novel therapeutic approaches.
Focus on developing targeted therapies for better disease management and patient care.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
